Literature DB >> 25370943

Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression.

Fu-Biao Kang1, Ling Wang2, Dong Li3, Yin-Ge Zhang3, Dian-Xing Sun1.   

Abstract

B7 family members are aberrantly expressed on the human hepatocellular carcinoma (HCC) cell surface, and induce local and systemic immunosuppression. Tumor-associated macrophages (TAMs) are a significant immune cell subpopulation in HCC and may be induced to express co-inhibitory molecules including B7 homologue 3 (B7-H3). In the present study, 79.3% of the HCC tissue samples showed high expression of B7-H3 which was positively correlated with the number of TAMs in the evaluated cancer tissues. Furthermore, high levels of TAMs or B7-H3 were associated with a shorter survival time of the HCC patients. In vitro, B7-H3 expression was upregulated at both the mRNA and protein levels in phorbol 12-myristate 13-acetate (PMA)-induced THP-1 cells cocultured with HepG2 cells in a Transwell system. In addition, B7-H3 promoted PMA-induced THP-1 cells to differentiate into the M2 phenotype, with evidence of increases in arginase 1 (Arg1), vascular endothelial cell growth factor (VEGF) and macrophage-derived chemokine (CCL22) mRNA following coculture with HepG2 cells. However, this phenomenon was abrogated through knockdown of B7-H3 by RNA interference or by blocking the signal transducer and activator of trans-cription 3 (STAT3) signaling pathway. Overall, these results suggest that the B7-H3-mediated STAT3 signaling pathway is an important mechanism for inducing M2-type polarization of TAMs, which accelerates HCC development. Our findings may support the development of novel therapeutic strategies for HCC patients through the skewing of the TAM phenotype by targeting the B7-H3 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25370943     DOI: 10.3892/or.2014.3587

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

1.  High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder.

Authors:  Zhili Xu; Ling Wang; Jianhua Tian; Hongwei Man; Pengfei Li; Baoen Shan
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

2.  Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α.

Authors:  Sangbin Lim; Hao Liu; Luciana Madeira da Silva; Ritu Arora; Zixing Liu; Joshua B Phillips; David C Schmitt; Tung Vu; Steven McClellan; Yifeng Lin; Wensheng Lin; Gary A Piazza; Oystein Fodstad; Ming Tan
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

3.  Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma.

Authors:  Ling Wang; Na-Na Cao; Shan Wang; Hong-Wei Man; Peng-Fei Li; Bao-En Shan
Journal:  Tumour Biol       Date:  2015-09-28

Review 4.  Tumor-associated macrophages in cancers.

Authors:  W Hu; X Li; C Zhang; Y Yang; J Jiang; C Wu
Journal:  Clin Transl Oncol       Date:  2015-08-12       Impact factor: 3.405

Review 5.  Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications.

Authors:  Jun Wei; Peiwen Chen; Pravesh Gupta; Martina Ott; Daniel Zamler; Cynthia Kassab; Krishna P Bhat; Michael A Curran; John F de Groot; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

6.  Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.

Authors:  Dan Yu; Jinzhang Cheng; Kai Xue; Xue Zhao; Lianji Wen; Chengbi Xu
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

Review 7.  Experience with regorafenib in the treatment of hepatocellular carcinoma.

Authors:  Alessandro Granito; Antonella Forgione; Sara Marinelli; Matteo Renzulli; Luca Ielasi; Vito Sansone; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  Therap Adv Gastroenterol       Date:  2021-05-28       Impact factor: 4.409

8.  Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.

Authors:  Dong-Jun Park; Pil-Soo Sung; Gil-Won Lee; Sungwoo Cho; Sung-Min Kim; Byung-Yoon Kang; Wonhee Hur; Hyun Yang; Soon-Kyu Lee; Sung-Hak Lee; Eun-Sun Jung; Chang-Ho Seo; Joseph Ahn; Ho-Joong Choi; Young-Kyoung You; Jeong-Won Jang; Si-Hyun Bae; Jong-Young Choi; Seung-Kew Yoon
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

9.  MicroRNA miR-29a Inhibits Colon Cancer Progression by Downregulating B7-H3 Expression: Potential Molecular Targets for Colon Cancer Therapy.

Authors:  Jin Wang; Xiaojuan Chen; Chen Xie; Mingbing Sun; Chenrui Hu; Zhe Zhang; Lipeng Luan; Jin Zhou; Jian Zhou; Xinguo Zhu; Jun Ouyang; Xiaoqiang Dong; Dechun Li; Jianglei Zhang; Xin Zhao
Journal:  Mol Biotechnol       Date:  2021-06-07       Impact factor: 2.695

Review 10.  Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.

Authors:  Alessandro Granito; Sara Marinelli; Antonella Forgione; Matteo Renzulli; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  J Hepatocell Carcinoma       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.